Carbon Dioxide

drug
On this page

Also known as Carbonic acidDry ice (solid form)E-290E290INS NO.290INS-290NSC-81688Carbondioxide

Summary

Carbon Dioxide (CHEMBL1231871) is an approved small-molecule vasodilator agent (ATC V03AN02); indicated across 9 conditions including panic disorder and trigeminal neuralgia.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: V03AN02
  • Indications: 9 conditions
  • Clinical trials: 32
  • Chemistry: 44.009 Da · CO2

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL1231871
NameCarbon Dioxide
TypeSmall molecule
Max phase3
FDA approvedyes
PubChem CID280
ChEBICHEBI:16526
ATCV03AN02
Molecular formulaCO2
Molecular weight44.009
InChIKeyCURLTUGMZLYLDI-UHFFFAOYSA-N

SMILES: C(=O)=O

IUPAC name: carbon dioxide

ChEBI definition: A one-carbon compound with formula CO2 in which the carbon is attached to each oxygen atom by a double bond. A colourless, odourless gas under normal conditions, it is produced during respiration by all animals, fungi and microorganisms that depend directly or indirectly on living or decaying plants for food.

Pharmacological roles (ChEBI): vasodilator agent, anaesthetic, antagonist, greenhouse gas.

Other ChEBI roles (chemical / environmental): solvent, human metabolite, food packaging gas, food propellant, refrigerant, Saccharomyces cerevisiae metabolite, Escherichia coli metabolite, mouse metabolite.

Also known as: Carbon dioxide, Carbonic acid, Dry ice (solid form), E-290, E290, INS NO.290, INS-290, NSC-81688, Carbondioxide, CARBON DIOXIDE

Patent coverage: 1,076,780 distinct patent families (2,176,373 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 2,151,865 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

9 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
panic disorder2MONDO:0005383EFO:0004262
trigeminal neuralgia2MONDO:0008599EFO:1001219
perennial allergic rhinitis2MONDO:0024332EFO:1001417
sleep apnea syndrome2MONDO:0005296EFO:0003877
migraine disorder2MONDO:0005277MONDO:0005277
heart failure1MONDO:0005252EFO:0003144
respiratory failure1MONDO:0021113EFO:0009842

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 32.

Phase distribution

PhaseTrials
Not specified19
PHASE26
PHASE14
PHASE42
EARLY_PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00464022PHASE4COMPLETEDCO2 Insufflation During Double Balloon Enteroscopy
NCT03287687PHASE4COMPLETEDSafety and Efficacy of CO2 for Endoscopy
NCT07596628PHASE2NOT_YET_RECRUITINGsiRNA Microneedle Patches for Earlobe Keloid Post-Surgical Scars
NCT00325312PHASE2COMPLETEDSubcutaneous Carbon Dioxide Insufflations for Acute Non Specific Neck Pain
NCT01041924PHASE2UNKNOWNDynamic Carbon Dioxide (CO2) Administration for Sleep Apnoea
NCT02113449PHASE2COMPLETEDMarket Potential of Carbon Dioxide Nasal Spray
NCT02631694PHASE2UNKNOWNDisruption of Memory Reconsolidating as a Treatment for Panic Disorder
NCT04058132PHASE2TERMINATEDCerebrovascular Reactivity Assessed With fNIRS as a Biomarker of TCVI After Acute Traumatic Brain Injury in Military
NCT01049256PHASE1UNKNOWNThe Cyclocapnic Method for Measurement of Chemosensitivity
NCT01050179PHASE1UNKNOWNChemoreflex Gain on Exercise
NCT02473354PHASE1COMPLETEDPredictors of Opioid-Induced Respiratory Depression (OIRD)
NCT03998631PHASE1UNKNOWNComparison of Carbon Dioxide and Saline Flush to Saline Flush in TEVAR and TAVI Procedures to Reduce Cerebral Ischemia
NCT07420530EARLY_PHASE1RECRUITINGRespiratory and Real-time Dynamics in Exercise-Induced Paradoxical Vocal Fold Motion
NCT04157179Not specifiedRECRUITINGCerebral Oxygen Metabolism in Children
NCT04258774Not specifiedENROLLING_BY_INVITATIONThe Effect of Respiratory Challenge on the BOLD Signal
NCT04406818Not specifiedRECRUITINGMetabolic and Hemodynamic Reserve in Pediatric SCA
NCT05761756Not specifiedRECRUITINGOxygen Toxicity: Mechanisms in Humans
NCT06338865Not specifiedRECRUITINGShort Title: Standard vs. Lower Pressure Pneumoperitoneum
NCT06865378Not specifiedENROLLING_BY_INVITATIONThe Correlation Between Intraoperative End Tidal Carbon Dioxide, Perfusion Index and Pulse Variability Index on Postoperative Nausea Vomiting and Pain
NCT07463742Not specifiedNOT_YET_RECRUITINGTranscriptomic Profile Changes in Benign Tracheal Stenosis: Wedge Resection vs. Radial Incision
NCT00618410Not specifiedCOMPLETEDIntranasal CO2 for Allergic Rhinitis
NCT00719342Not specifiedCOMPLETEDEffect of Breathing a Mixture of 92% Oxygen (O2) + 8% Carbon Dioxide (CO2) on Flicker Induced Blood Flow Changes in Ocular Perfusion
NCT01045005Not specifiedWITHDRAWNDoppler Ultrasound Investigation of Microcirculations
NCT01344499Not specifiedCOMPLETEDClearance Rate of Peritoneal Fluid After Full Conditioning Pneumoperitoneum
NCT02790359Not specifiedCOMPLETEDCarbon Dioxide Insufflation Versus Conventional Air Insufflation
NCT02958722Not specifiedCOMPLETEDComparison Between Two Different Distention Medium in Diagnostic Hysteroscopy
NCT03141697Not specifiedCOMPLETEDThe Use of CO2 in Routine-Colonoscopy
NCT03264027Not specifiedCOMPLETEDCarbon Dioxide Versus Air Insufflation for the Application of Argon Plasma to Reduce the Gastrojejunal Anastomosis
NCT04541667Not specifiedCOMPLETEDIs End Tidal CO2 Level Elevation During Upper Endoscopy With CO2 Gas Insufflation Physiologically Significant
NCT04947982Not specifiedUNKNOWNLow Versus Standard Pressure Pneumoperitoneum
NCT05350137Not specifiedCOMPLETEDApplication of Carbon Dioxide for Identifying the Intersegmental Plane in Thoracoscopic Segmentectomy
NCT05873335Not specifiedCOMPLETEDIn Vivo Pulse Oximeter Validation Study

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.